Ardelyx, Inc.- Bad News for Patients and Investors

Advances in biotechnology can have amazing results for patients, but bringing a drug to market can be a risky business for companies and investors. And the risks don’t end once a therapy is on the market, as investors in Ardelyx, Inc. learned when they lost over thirty percent of their investments. These shareholders claim that their losses aren’t the result of risky investing but of fraud by Ardelyx. Any shareholder who incurred a loss due to Ardelyx’s alleged misconduct can join the recently-filed lawsuit.